Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Captopril nebulization in COVID-19 pneumonia
2020-001700-42Phase 2Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in coronavirus pneumonia and coronavirus disease 2019 (COVID-19) comparing Captopril nebulization + standard of care with Standard of care alone (2 arms). Primary endpoint: 14-day invasive mechanical ventilation-free survival. Started Apr 2020; status: active.
02
Drugs
captopril
03
Conditions
coronavirus pneumoniacoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001700-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001700-42.